Description
A glucagon-like peptide-1 (GLP-1) receptor agonist with 94% homology to human GLP-1. FDA-approved as Ozempic (weekly injection for T2DM), Wegovy (weekly injection for obesity/overweight), and Rybelsus (oral daily for T2DM). Produced by Novo Nordisk. One of the most commercially successful drugs in history.
Benefits:
Significant weight loss (avg 15-17% with Wegovy at 68 weeks); type 2 diabetes blood glucose control (superior to many comparators); cardiovascular risk reduction (SELECT trial – 20% reduction in MACE); appetite suppression; potential neuroprotective/Alzheimer’s effects under study; NASH/liver fat reduction
Side Effects:
Nausea (very common – up to 40% initially); vomiting; diarrhea; constipation; gastroparesis risk; pancreatitis (rare); gallbladder disease; thyroid C-cell tumor risk (animal studies – avoid with MEN2/medullary thyroid carcinoma history); injection site reactions; hypoglycemia (with concurrent insulin/sulfonylureas); muscle mass loss
For laboratory research only — not for human consumption.
Reviews
There are no reviews yet.